Multiple Sclerosis Clinical Trial

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

Summary

The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of primary-progressive multiple sclerosis (PPMS) or non-relapsing secondary-progressive multiple sclerosis (SPMS) and no relapses for at least 24 months.
Evidence of physical disability according to Expanded Disability Status Scale (EDSS) or Timed 25-Foot Walk (T25FW) or 9-Hole Peg Test.

Exclusion Criteria:

Treatment with any of the following within the 6 months prior to Screening: natalizumab; cyclosporine; azathioprine; methotrexate; mycophenolate mofetil; intravenous immunoglobulin (IVIg); any interferon product; and intravenous (IV), oral, or intrathecal corticosteroids for the purposes of disease modification.
Treatment with the following within 1 year prior to Screening: cyclophosphamide or alemtuzumab.

Study is for people with:

Multiple Sclerosis

Phase:

Phase 2

Estimated Enrollment:

123

Study ID:

NCT03737812

Recruitment Status:

Completed

Sponsor:

AbbVie

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 37 Locations for this study

See Locations Near You

St. Josephs Hospital and Med Center /ID# 202809
Phoenix Arizona, 85013, United States
Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 202448
Berkeley California, 94705, United States
The Research Center of Southern California /ID# 202802
Carlsbad California, 92011, United States
Vladimir Royter MD /ID# 202483
Hanford California, 93230, United States
Stanford MS Center /ID# 202445
Palo Alto California, 94304, United States
UC Davis Health-Neurological Surgery /ID# 202485
Sacramento California, 95817, United States
UCSF School of Medicine - Neurology /ID# 203194
San Francisco California, 94143, United States
University of Colorado School of Medicine, Dept of Neurology /ID# 202807
Aurora Colorado, 80045, United States
Advanced Neurosciences Research, LLC /ID# 203072
Fort Collins Colorado, 80528, United States
Rowe Neurology Institute /ID# 202744
Lenexa Kansas, 66214, United States
Duplicate_Parexel International /ID# 202747
Baltimore Maryland, 21225, United States
International Neurorehabilitation Institute /ID# 213333
Lutherville Maryland, 21093, United States
Michigan Institute for Neurological Disorders (MIND) /ID# 202470
Farmington Hills Michigan, 48334, United States
Memorial Neurological Institute and Center for Multiple Sclerosis /ID# 206327
Owosso Michigan, 48867, United States
Ridgeview Specialty Clinic Chaska - Neurology /ID# 204384
Chaska Minnesota, 55318, United States
Washington University-School of Medicine /ID# 202899
Saint Louis Missouri, 63110, United States
The MS Center for Innovations in Care at Missouri Baptist Medical Center /ID# 205432
Saint Louis Missouri, 63131, United States
Cleveland Clinic Lou Ruvo Cent /ID# 204744
Las Vegas Nevada, 89106, United States
Oklahoma Med Res. Foundation /ID# 203442
Oklahoma City Oklahoma, 73104, United States
Providence Neurological Specialties - West /ID# 203193
Portland Oregon, 97225, United States
Advanced Neurosciences Institute /ID# 204555
Franklin Tennessee, 37064, United States
KCA Neurology - Franklin /ID# 202912
Franklin Tennessee, 37067, United States
Neurology Consultants of Dallas - LBJ Fwy /ID# 203102
Dallas Texas, 75243, United States
Central Texas Neurology Consul /ID# 203108
Round Rock Texas, 78681, United States
Integrated Neurology Services /ID# 202743
Alexandria Virginia, 22310, United States
Evergreen Neuroscience Institute /ID# 204205
Kirkland Washington, 98034, United States
Virginia Mason Medical Center /ID# 205439
Seattle Washington, 98101, United States
Swedish MS Center /ID# 202904
Seattle Washington, 98122, United States
West Virginia Univ School Med /ID# 202849
Morgantown West Virginia, 26506, United States
Froedtert Memorial Lutheran Hospital /ID# 202618
Milwaukee Wisconsin, 53226, United States
University of British Columbia - MS & NMO Clinical Trials Group, Djavad Mowafagh /ID# 203536
Vancouver British Columbia, V6T 1, Canada
Duplicate_London Health Sciences Centre - University Hospital /ID# 203538
London Ontario, N6A 5, Canada
Ottawa Hospital Research Institute /ID# 203058
Ottawa Ontario, K1H 8, Canada
Unity Health Toronto - St. Michael's Hospital /ID# 206213
Toronto Ontario, M5B 1, Canada
Recherche Sepmus Inc. /ID# 212852
Greenfield Park Quebec, J4V 2, Canada
Centre Hospitalier de l'Universite de Montreal - CRCHUM /ID# 203869
Montreal Quebec, H2X 0, Canada
Montreal Neurological Institut /ID# 203868
Montreal Quebec, H3A 2, Canada

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Phase 2

Estimated Enrollment:

123

Study ID:

NCT03737812

Recruitment Status:

Completed

Sponsor:


AbbVie

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.